Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oncothyreon -- Ignore unavailable to you. Want to Upgrade?

To: marvin friedman who wrote (876)	5/26/1999 12:39:00 AM
From: Claude Robitaille	Respond to of 2344

Biotech Publicity The Forbes magazine supplement ASAP Cancer Biomira, Alberta, Canada; founded 1985; www.biomira.com; 1998 revenues: $3.9M; projected 1999 revenues: $1.3M Biomira's vaccine for breast cancer, Theratope, is in Phase III clinical trials. Chiron has marketing and distribution rights. Biomira also sold off its diagnostics division to focus more on vaccines. Corixa, Seattle, WA; founded 1994; www.corixa. com; 1998 revenues: $18.3M; projected 1999 revenues: $24.5M The leading company for the development of antigens, Corixa maintains partnerships with SmithKline Beecham and PMC. Progenics Pharmaceuticals, Tarrytown, NY; founded 1988; www. progenics.com; 1998 revenues: $14M; projected 1999 revenues: $23M Under a partnership with Bristol-Myers Squibb, Progenics has the first antigen-specific vaccine ever in Phase III clinical trials. It will treat malignant melanoma.